A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients must be adult (age ≥ 18 years age) post-menopausal* women
Patients must be diagnosed with advanced breast cancer (histologically or cytological confirmation required) i.e. TNM stage III or IV disease (locally advanced or metastatic breast cancer) or locoregional recurrent disease, not suitable for treatment by local surgery or radiation therapy
Measurable or evaluable disease
Patients with ER/PR positive tumour or ER/PR unknown status
Patients must be suitable for endocrine treatment with anastrozole
Prior adjuvant chemotherapy or endocrine therapy for early breast cancer is allowed, provided such treatment was completed at least twelve months prior to study enrollment
Performance status 0-2 (As per WHO Classification)
Concurrent use of bisphosphonates is permitted.
Patients must give their written informed consent for participation in the study
Patients with tumors known to be estrogen and progesterone receptor-negative.
Estrogen hormone replacement therapy, concurrently or within 6 weeks before randomization
Extensive visceral involvement (significant hepatic involvement, brain metastasis or pulmonary involvement > 50% of the lungs); serum liver enzymes SGOT and SGPT should be no greater than five times the upper limit of the reference range
Patients received bone marrow transplantation before randomization
Any concurrent medical illness (uncontrolled cardiac disease or diabetes mellitus) or laboratory abnormalities that would compromise safety or prevent interpretation of results
An estimated survival of less than 3 months from the start of Study drug treatment based on clinical judgment.
Any systemic investigational drug within the thirty days of enrollment into study